ponatinib,blinatumomab
takeda,incyte,otsuka,amgen
['leusm', 'ponatinib', 'ph+ all']
congress #eha2023 | presents efficacy &amp; safety of mini-hyper cvd+ponatinib followed by blina+ponatinib in 17 pts with ph+ all. cmr, crd &amp; os rates were 82%, 92% &amp; 81% respectively. combination was well tolerated.
#leusm #allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm